Nadroparin
Title: Nadroparin
Additional Names: Tedegliparin
Literature References: Low molecular weight fraction of heparin, q.v., prepd from porcine mucosal heparin by selective ethanol precipitation. Mean mol wt 4500 daltons. Prepn: J.-C. Lormeau et al., DE 2944792; eidem, US 4486420; US 4692435 (1980, 1984, 1987 all to Choay); J. Choay et al., Thromb. Res. 18, 573 (1980). Comparison with unfractionated heparin: G. F. Gensini et al., Haemostasis 14, 466 (1984); M. D. Vandenbroek, B. Bordes, J. Pharm. Clin. 5, 35 (1986); C. Doutremepuich et al., Thromb. Res. 43, 691 (1986). Pharmacokinetics and bioavailability in humans: J. Harenberg et al., ibid. 44, 549 (1986). Clinical trial in prophylaxis of postoperative thromboembolism: V. V. Kakkar, Nouv. Rev. Fr. Hematol. 26, 277 (1984); V. V. Kakkar, W. J. G. Murray, Br. J. Surg. 72, 786 (1985); in acute ischemic stroke: R. Kay et al., N. Engl. J. Med. 333, 1588 (1995).
 
Derivative Type: Calcium salt
Manufacturers' Codes: CY-216
Trademarks: Fraxiparine (Sanofi Winthrop)
 
Therap-Cat: Antithrombotic.
Keywords: Antithrombotic.

Others monographs:
FlosequinanClofibrateSodium MetabisulfiteVomicine
AzidamfenicolLupulinEsmololMetobromuron
IodineMetofolineErgosineSkimmianine
Tetraglycine HydroperiodideMethyl Allyl TrisulfideTriacetinPentryl
©2016 DrugLead US FDA&EMEA